We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Non‐Invasive Prenatal Diagnosis of Spinal Muscular Atrophy Validated

By LabMedica International staff writers
Posted on 08 Oct 2019
The discovery of cell‐free DNA (cfDNA) in maternal plasma has enhanced the development of non‐invasive prenatal testing (NIPT). More...
Although NIPT for fetal aneuploidies has already been clinically applied, non‐invasive prenatal diagnosis for many single‐gene disorders remains on the developing stage.

Droplet digital PCR is a technology with high sensitivity, specificity, and accuracy to detect and analyze low-abundance nucleic acids. Its high resolution is guaranteed by millions of oil droplets generated per test. Utilizing digital PCR, the feasibility of non‐invasive prenatal diagnosis (NIPD) for fetal monogenic disorders has been proved in several studies analyzing cfDNA.

Medical Geneticists at the Central South University (Changsha, China) recruited pregnant women seeking Spinal Muscular Atrophy (SMA) prenatal diagnosis on 16 ~ 22 weeks of gestation for a study. All of the pregnancies had undergone non‐invasive prenatal screening for fetal aneuploidies by next‐generation sequencing (NGS).

The scientists extracted cell‐free DNA from maternal plasma using the QIAamp Circulating Nucleic Acid Kit and the concentrations of cfDNA samples were tested on Qubit. Amniotic fluid was obtained by amniocentesis, from which fetal genomic DNA was extracted by the phenol‐chloroform method. RainDrop droplet digital PCR was performed following standard protocols. SMN1/SMN2 copy numbers of all participants and fetuses were quantified by the multiplex ligation‐dependent probe amplification (MLPA) analysis using SALSA MLPA Kit.

The team reported that the concordance rate with the results of MLPA testing of amniocyte DNA was 94.12% in one test set and 90% in another set of participants. For all tests with a classifiable result, the percent of agreement with the results of MLPA testing of amniocyte DNA was up to 100% (25/25). The authors concluded that they had developed a direct, rapid, and low‐cost technique, which has a potential to be utilized for first‐trimester non‐invasive prenatal diagnosis and screening for spinal muscular atrophy with considerable reliability and feasibility. The study was published on September 25, 2019, in the Journal of Clinical Laboratory Analysis.

Related Links:
Central South University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Urine Analyzer
respons® UDS100
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.